NBIX - Neurocrine Biosciences Non-GAAP EPS of $0.84 misses by $0.05 revenue of $378.2M beats by $34.75M
- Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q2 Non-GAAP EPS of $0.84 misses by $0.05 .
- Revenue of $378.2M (+30.9% Y/Y) beats by $34.75M .
- INGREZZA (valbenazine) 2022 Net Product Sales Guidance Raised to $1.35 - $1.40 Billion
For further details see:
Neurocrine Biosciences Non-GAAP EPS of $0.84 misses by $0.05, revenue of $378.2M beats by $34.75M